Mar 20, 2003 | NEWS
CAMBRIDGE, Mass – Genzyme General (Nasdaq: GENZ), a division of Genzyme Corp., announced today that it has begun enrolment in a clinical trial evaluating the use of its Myozyme™ recombinant human acid alpha -Glucosidase enzyme as a potential treatment for Pompe...
Dec 2, 2002 | NEWS
An update by Genzyme regarding treatment for Pompe disease. Q: What is the status of the Pompe program? Genzyme has made strong progress within its Pompe disease program since its decision earlier this year to move forward with an internally developed product...
Oct 2, 2002 | NEWS
IBaarn, October 2nd 2002 Dear IPA members, Herewith I would like to inform you about the IPA/Genzyme telephone conference of September 24 2002. We discussed issues concerning the production, the transition, new trials and the meeting with the Erasmus University, VSN,...
Jul 4, 2002 | NEWS
In July 2002, Genzyme began the transition of the nine transgenic (rabbit derived enzyme) patients to the CHO derived product. Three of the nine patients (infantile patients in the Netherlands) will remain on the transgenic enzyme until April 2003, when supply will be...
Apr 18, 2002 | NEWS
Board members of the IPA, the International Pompe Association, met with key representatives of Genzyme in Cambridge, Massachusetts on April 16-17, 2002. The IPA members in attendance were: Randall House, AMDA-US; Marylyn House, AMDA-US, Ria Broekgaarden, VSN-The...
